During a characteristically bizarre and rambling press conference, Donald Trump yesterday fought back against lurid reports from Russia, but two policies nevertheless emerged as priorities:
The US Congress may pass the 21 Century Cures Act this week, a major new piece of legislation affecting healthcare, the FDA and pharma - but the battle for what measures will be included an
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular diso
In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Jameka Hill, senior director of clinical trial health equity at Moderna.
